Cytyc Corporation Announces Redemption of 2.25% Senior Convertible Notes Due 2024
PRNewswire-FirstCall
MARLBOROUGH, Mass.

MARLBOROUGH, Mass., March 12, 2009   /PRNewswire-FirstCall/ -- Cytyc Corporation ("Cytyc"), a wholly-owned subsidiary of Hologic, Inc. (NASDAQ: HOLX), today announced that it is delivering a redemption notice to the holders of its 2.25% Senior Convertible Notes due 2024 (CUSIP Nos. 232946 AA 1 and 232946 AB 9) (the "Notes") in accordance with Section 3.02 of the indenture, dated as of March 22, 2004 (the "Indenture"), between Cytyc and U.S. Bank Trust National Association, as trustee, under which the Notes were issued. The aggregate principal amount of the Notes outstanding to be redeemed is $298,000.

The redemption notice informs holders of the Note that Cytyc has set March 31, 2009 as the date upon which it will redeem all then outstanding Notes in full at a redemption price equal to 100% of the principal amount of each Note to be redeemed together with accrued and unpaid interest, if any, to, but excluding March 31, 2009 on each such Note.

About Hologic

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications.


Contact:
Deborah R. Gordon
Vice President, Investor Relations
Hologic, Inc.
Tel: 781.999.7716


Frances Doria
Director, Investor Relations
Hologic, Inc.
Tel: 781.999.7377

 

SOURCE: Cytyc Corporation